Beta Bionics, una empresa de tecnología de la diabetes, recibe calificaciones de analistas mixtos, pero ve compras de información privilegiada, trading cerca de $20. Beta Bionics, a diabetes tech firm, receives mixed analyst ratings but sees insider buys, trading near $20.

Beta Bionics, una empresa que desarrolla soluciones para la diabetes, ha obtenido calificaciones de analistas mixtos, incluyendo "superación" y "neutral", con un precio objetivo promedio de $24,83 y un consenso de "Compra Moderada". Beta Bionics, a company developing diabetes solutions, has garnered mixed analyst ratings, including "outperform" and "neutral," with an average target price of $24.83 and a "Moderate Buy" consensus. Las acciones de la compañía, que se abrió a $19.99, ha visto importantes compras de acciones por parte de los principales accionistas e informantes. The company's stock, which opened at $19.99, has seen significant share purchases by major shareholders and insiders. Beta Bionics, fundada en 2015, tiene su sede en Irvine, CA. Beta Bionics, founded in 2015, is based in Irvine, CA.